Mark E Scott

USPTO Granted Patents = 19 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 6.8

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

Edmonton, CA (US) (2016)
Andover, MA (US) (2013 - 2018)
Alberta, CA (2019)
Kirkland, CA (2019)
Edmonton, CA (2018 - 2022)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

patents

3 out of 919

Gilead Sciences, Inc.

patents

1 out of 832,680

Other

patents

Years Active: 2013-2022

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11279710 - Processes for preparing ACC inhibitors and solid forms thereof (2022-03-22),

2. 10815214 - Regioselective N-2 arylation of indazoles (2020-10-27),

3. 10745412 - Processes for preparing ACC inhibitors and solid forms thereof (2020-08-18),

4. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2020-06-23),

5. 10519165 - Processes for preparing ACC inhibitors and solid forms thereof (2019-12-31),

6. 10435386 - Regioselective N-2 arylation of indazoles (2019-10-08),

7. 10344000 - Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-07-09),

8. 10287272 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2019-05-14),

9. 10275332 - System for interacting with a web visitor (2019-04-30),

10. 10072025 - Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors (2018-09-11),

11. 10059705 - Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors (2018-08-28),

12. 9957265 - N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors (2018-05-01),

13. 9957264 - Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors (2018-05-01),

14. 9725445 - Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors (2017-08-08),

15. 9580407 - Regioselective N-2 arylation of indazoles (2017-02-28),

Title: Mark E. Scott: Innovator in Pharmaceutical Patents

Introduction

Mark E. Scott is a prominent inventor based in Edmonton, Canada, known for his significant contributions to the field of pharmaceuticals through his 19 patents. His innovative approaches have led to advancements in treatments for diseases with unmet medical needs.

Latest Patents

Scott's recent patents include groundbreaking work on "Processes for preparing ACC inhibitors and solid forms thereof," which details solid forms, including salts or co-crystals, of a compound exhibiting Acetyl-CoA carboxylase (ACC) inhibitory activity. This innovation aims to address ACC-mediated diseases. Another notable patent is for the "Regioselective N-2 arylation of indazoles," describing an efficient method for preparing asymmetric compounds using copper-catalyzed carbon-nitrogen cross-coupling. This process is particularly relevant for developing poly (ADP-ribose) polymerase (PARP) inhibitors, offering potential therapeutic options in cancer treatment.

Career Highlights

Over the course of his career, Mark E. Scott has made significant contributions while working at major pharmaceutical companies, including Merck Sharp & Dohme Corporation and Gilead Sciences, Inc. His diverse experiences within these organizations have fostered a robust foundation for his innovative research and development efforts.

Collaborations

In his journey, Scott has collaborated with esteemed colleagues such as Peter H. Fuller and Christopher J. Dinsmore. These partnerships have enabled the exchange of ideas and facilitated advancements in their collective research endeavors, further enhancing the impact of their innovations.

Conclusion

Mark E. Scott's impressive portfolio of patents reflects his dedication to addressing critical health challenges through innovative solutions. His work continues to inspire new developments in the pharmaceutical industry, establishing him as a significant figure in the realm of medicinal chemistry and patentable inventions.

This text is generated by artificial intelligence and may not be accurate.